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Abstract 
ABHD5 protein is widely involved in lipid and energy homeostasis. Mutations in the ABHD5 
gene are associated with the onset of Neutral Lipid Storage Disease with Ichthyosis (NLSDI), 
historically known as Chanarin Dorfman Syndrome (CDS). CDS is a rare autosomal recessive 
lipid storage disease, characterized by non-bullous congenital ichthyosiform eritrhoderma 
(NCIE), hepatomegaly and liver steatosis. Myopathy, neurosensory hearing loss, cataracts, 
nystagmus, strabismus, and mental impairment are considered additional findings. To date, 151 
CDS patients have been reported all over the world. Here we described two additional families 
with patients affected by CDS from Turkey. Our patients were a 42 and 22-years old men, 
admitted to the Hospital for congenital ichthyosis. Hepatic steatosis and myopathy were also 
detected in both patients. ABHD5 molecular analysis revealed the presence of N209* mutation. 
Our data enlarge the cohort of CDS patients and provide a revision of muscle clinical findings 
for this rare inborn error of neutral lipid metabolism. 
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 Neutral Lipid Storage Diseases (NLSDs) are a 
heterogeneous group of autosomal recessive disorders 
characterized by an increased accumulation of 
triacylglycerols (TAGs) in several tissues. Two forms of 
NLSDs are known: NLSD with ichthyosis (NLSDI), also 
known as Chanarin-Dorfman syndrome (CDS; MIM 
275630), and NLSD with myopathy (NLSDM; MIM 
610717).1 In 1974, Dorfman studied the cases of two 
sisters and two unrelated patients with congenital 
ichthyosiform erythroderma and lipid accumulations in 
the granulocytes.2 Nhe next year also Chanarin observed 
the presence of similar symptoms in a 22-years-old Asian 
woman. He excluded any other disease linked to lipid 
metabolism assuming impairment either of cytoplasmic 
lipase activity or of fatty acid transport into 
mitochondria.3 The major findings of CDS are non-
bullous congenital ichthyosiform erythroderma (NCIE), 
hepatomegaly, and liver steatosis.4 Other variable 
features are muscle weakness, ataxia, neurosensory 
hearing loss, sub-capsular cataracts, nystagmus, 
strabismus and mental retardation.5,6 Patients are 
sometimes born as collodion babies.7 The clinical 
diagnosis is based on observation of Jordan’s bodies, 
which are characteristic cytoplasmic vacuoles,8 on 
granulocytes, and then confirmed by genetic testing. The 
onset of CDS is caused by mutations in the ABHD5 
gene.9 This gene is located on chromosome 3p21, 
contains seven exons and codifies for the α/β-hydrolase 
domain-containing protein 5, a protein of the esterase, 
lipase and thioesterases subfamily. The human ABHD5 
is a 349 amino acid-long protein, able to activate adipose 
triglyceride lipase (ATGL).10 So far, although 151 CDS 
patients have been reported all over the world, only 103 
of them have undergone molecular testing.1,11,12 While 
most cases have been reported in the Mediterranean and 
Middle East regions, some cases have also been 
described in China, Japan, India and Brazil.4,13-18 The 
largest number of patients (40 cases) has been described 
in Turkey, mainly due to the high incidence of 
consanguineous marriages.5,13,19 The most common 
mutation in the ABHD5 is the N209*, which has been 
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identified in 52% (21/40) of patients from Turkey and in 
16% of all CDS patients (24/151). Here, we report the 
molecular and clinical characterization of two additional 
Turkish families with patients affected by CDS. Genetic 
analysis revealed the N209* mutation, confirming the 
diagnosis. 
Materials and Methods 
Dermatological, neurological, hepatic and muscle 
investigation were performed. Clinical data were 
collected following ethical principles reported in the 
Declaration of Helsinki. Peripheral blood smears were 
stained with May-Grünwald Giemsa to reveal Jordan’s 
bodies in neutrophils using a light microscopy. Genomic 
DNA was extracted from blood samples, and ABHD5 
coding regions and their intron/exon boundaries were 
examined by PCR analysis. Primer sequences and 
amplification protocol were previously described5. 
Finally, all PCR products were purified and sequenced 
(Eurofins Genomics, DNA sequencing service). 
Molecular analysis was carried out after obtaining the 
written, informed consents. 
Results and Discussion 
Patient 1 is a 42-year-old man admitted to Adana 
outpatient clinic for congenital ichthyosis. Due to his 
complaints, he only used topical moisturizers. His 
parents were not consanguineous, and he had 9 siblings 
(Figure 1a). His mother and two siblings had congenital 
ichthyosis. Dermatological examination of patient 
revealed widespread ichthyosis containing facial region, 
trunk, extensor and flexural regions, and scalp. Individual 
scale over the trunk was white, fine, translucent and semi-
adherent, while that on limbs and face was grey brown, 
larger in size, polygonal and adherent. There were no 
bullous lesions. Involvement of palms and soles, dental 
anomaly and nail dystrophy were absent. 
Intracytoplasmic vacuoles (Jordan’s anomaly) were 
detected in neutrophils on peripheral blood smear stained 
with May-Grünwald Giemsa (Figure 2a-b). Muscle 
strength, mental status and neurologic examination were 
normal, and the patient denied any hearing or visual 
problem. Liver transaminases, creatine kinase (CK) and 
serum triglyceride (TG) levels were elevated (alanine 
transaminase: 53 U/L [normal 5-35 U/L]; aspartate 
transaminase: 46 U/L [normal 5-17 U/L]; CK: 393 U/L 
[normal 22-200 U/L]; TG: 162 mg/dL [normal 35-130 
mg/dL]). Abdominal ultrasonography was compatible 
with grade I hepatic steatosis. Finally, electromyographic 
(EMG) examination was compatible with myopathy. 
After 3 months of systemic acitretin treatment (25 
mg/day), skin lesions of patient improved (Figure 2c-f). 
In agreement of what reported in other CDS patients, 
acitretin treatment led to a remarkable improvement in 
the appearance of the skin without any deleterious effect 
on liver function.20 Acitretin is a synthetic retinoid 
commonly used to treat severe skin problems, including 
ichthyosis. As a retinoid, it influences cellular division 
and differentiation of stratified structures of the 
epidermis. It exerts anti‐inflammatory effect and 
decreases epidermal cell proliferation, inducing 
differentiation, and cornification.21 
Patient 2 is a 22-year-old man admitted to Adana 
hospital because of suffering from congenital ichthyosis. 
His parents were relatives. He had two siblings, a sister 
and a brother, without clinical manifestations (Figure 
1b). Dermatological examination showed features 
similar to patient 1: widespread ichthyosis involving 
facial region, trunk, extensor and flexural regions, and 
scalp. On the trunk region there were white, fine, 
translucent and semi-adherent scales, while on limbs and 
face grey brown, large, polygonal and adherent scales 
(Figure 3a-e). Also in this case, there were neither 
bullous lesions nor involvement of palms and soles and 
 
 
Fig 1.  Characterization of two patients with CDS. Pedigree of CDS family 1 (a) and 2 (b). Localization of mutation 










N209* ABHD5 mutation in Chanarin Dorfman Syndrome 
Eur J Transl Myol 31 (2): 9796, 2021 doi: 10.4081/ejtm.2021.9796 
- 3 - 
 
nail dystrophy. The investigation of TAG abnormal 
storage displayed Jordan’s bodies in granulocytes (Figure 
3f-h). Evaluation of muscles highlighted normal strength, 
while EMG examination was consistent with myopathy. 
Hearing or visual, as well as mental or neurologic 
problems were not detected. Systemic evaluation was 
compatible with grade I hepatic steatosis and 
splenomegaly (153 mm), and laboratory tests showed an 
increase of liver enzymes (alanine transaminase: 82 U/L; 
aspartate transaminase: 59 U/L), CK (438 U/L) and 
serum TGs (178 mg/dL). In the examination of the oral 
mucosa, periodontitis was detected and panoramic 
radiograph revealed periodontal recession (Figure 3i-j). 
A low triglyceride diet supplemented with MCT oil was 
recommended to ameliorate hepatic and skin conditions, 
as previously reported in many CDS patients.17,18,22 The 
most common ABHD5 mutation was found in our 
patients in homozygous state. It consists of an insertion 
of a cytosine in position 594 (c.594insC) (Figure 1c). The 
addition of this supplementary base should lead to the 
production of a truncated protein (p.N209*). However, it 
is likely that the mRNA containing the premature stop 
codon is going to be degraded through the nonsense-
mediated mRNA decay (NMD) mechanism. Indeed, 
thanks to NMD the cells survey mRNA quality and are 
able to eliminate those mRNAs carrying premature 
termination triplets, preventing the synthesis of truncated 
proteins.23 In CDS patients the lack of ABHD5 protein 
determines a lower efficiency of ATGL activity. ATGL 
catalyzes the first step in the hydrolysis of TAGs 
generating diacylglycerols (DAGs) and free fatty acids 
(FAs), stored into cytoplasmic lipid droplets (LDs). DAG 
is the major substrate for hormone-sensitive lipase (HSL) 
activity, which determines the production of FA and 
 
Fig 2.  Clinical and microscopic findings of patient 
1. (a) and (b) Microscopic view of 
granulocutes stained with May-Grünwald 
Giemsa showing Jordan’s anomaly 
(arrows). Congenital ichthyosis on trunk 
and limbs before (c, black circle, and d) and 
after acitretin treatment (e, black circle, and 
f). The treatment ameliorated general skin 
conditions.    
 
 
Fig 3.  Clinical, microscopic and radiological 
findings of patient 2. Lamellar ichthyosis, 
shown by arrows, affecting facial region (a), 
trunk (b) and extremities (c-e). Jordan’s 
anomaly, indicated by arrows, in May-
Grünwald Giemsa-stained buffy coats (f-h). 
Periodontitis (i) and periodontal recession 
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MAG (monoacylglycerol). Finally, monoglyceride lipase 
(MGL) catabolizes MAG to FA and glycerol. FA 
generated from these processes are major energy 
substrates for cell.24,25 In CDS patients, the biochemical 
pathways reported above are largely compromised, 
because of ABHD5 molecular defect. Consequently, a 
systemic increase in the size and number of LDs, and a 
decrease of FA availability can be detected (Figure 4). 26 
In many articles, a beneficial effect on CDS patients 
following a low triglyceride diet supplemented with 
MCT oil has been reported. This is probably due both to 
a decrease accumulation of TAGs into LDs and an 
increase the availability of energy by the oxidation of 
 
 
Fig 4. Schematic representation of lipolytic mechanism. Under normal condition, triglycerides (TAGs), stored 
within the lipid droplets, are mobilized in response to energy demands.  TAG hydrolysis consists of a series 
of interrelated reactions. The primary intracellular lipase is the adipose triglyceride lipase (ATGL), which is 
activated through the interaction with ABHD5. ATGL promotes the release of the first fatty acid (FA) from 
TAGs, producing diacylglycerols (DAGs). The second lipase is the hormone-sensitive lipase (HSL), which 
leads to DAGs conversion into monoacylglycerols (MAGs). The lipolytic cascade culminates with the 
monoglyceride lipase (MGL) activity, which induces third FA and glycerol release. FAs are then delivered 
to mitochondria to produce energy through β-oxidation. In CDS condition, ABHD5 mutations cause a 
decrease of ATGL function, determining a defect of lipolytic pathway and a decrease of mitochondrial energy 
production. Supplementation of MCT oil provides medium-chain fatty acids containing 6 to 12 carbon atoms, 
































Fig. 5.  Frequency of muscle damage in CDS patients carrying different type of ABHD5 mutations. Percentage of 
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medium chain FAs. Total or partial loss of ABHD5 
function causes systemic manifestations, including 
ichthyosis, liver, muscle and central nervous system 
injury and elevation of hepatic and muscle enzymes. 
Ichthyosis is present in 100% of patients, while liver 
involvement can be detected in 85% of cases.1,12 
Accordingly, our patients show NCIE, which improved 
only after three months of acitretin treatment. They 
presented also hepatic steatosis and elevated levels of 
liver enzymes, therefore a specific diet was 
recommended. Moreover, in our patients, signs of 
myopathy were detected by electromyography and were 
associated to elevated levels of CK. ABHD5 gene 
analysis was performed in two thirds of CDS patients 
(103/151). Among them, 83 subjects harbored severe 
mutations (causing truncated protein or no protein 
production), while the remaining 20 presented mild 
mutations (missense mutations). In the first group of 
patients (severe mutations, including the p.N209* 
mutation), signs of myopathy and elevated level of 
muscles enzymes (CK or CPK) were detected in 36% and 
67,5% of cases, respectively. Moreover, 
electromyographic study revealed early recruitment with 
complete interphase pattern suggestive of myopathic 
pattern. Instead, in the second group of patients (missense 
mutations), myopathy and elevated level of muscles 
enzymes were observed in 15% and 30% of cases, 
respectively (Figure 5). The evaluation of myopathy and 
CK levels displayed significant difference between the 
two groups of patients, thus indicating that total or partial 
impairment of ABHD5 function causes a variable muscle 
damage, depending from the different availability of 
energy. As muscles require a lot of energy to work, the 
partial or total impairment of ABHD5 ability to activate 
ATGL hinders chemical reactions involved in TAG 
hydrolysis, determining their build-up inside muscle cells 
and energy levels too low. A skeletal muscle myopathy 
may occur, especially in the cases of total lack of ABHD5 
protein. Considering patients with myopathy, during 
successive decades of life (total: 33 patients), we can 
observe that the levels of CK and CPK increased 
similarly (2-3 fold) in all the intervals of times and that 
the myopathy, detected mainly by EMG examination, is 
mild or very mild in all cases and over time (Table 1).  
In conclusion, we described the clinical and genetic 
findings of two unreported CDS patients frmm different 
Turkish families. As CDS is an extremely rare genetic 
disorder and its pathophysiology is largely unknown, it is 
important to expand the cohort with novel patients and 
evaluate genotype-phenotype correlations. 
List of acronyms 
ABHD5- α/β-hydrolase domain-containing protein 5;  
ATGL - adipose triglyceride lipase;  
CDS - Chanarin-Dorfman Syndrome;  
CK - creatine kinase;  
DAG - diacylglycerol;  
EMG - electromyography;  
FA - fatty acid;  
HSL - hormone-sensitive lípase;  
LD - lipid droplet;  
MAG - monoacylglycerol;  
Table 1. Muscle involvement in CDS 
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Average age 5 ± 2,4 14 ± 2,25 36 ± 13,6 








CK level 1131 ± 642 (2-3 folds) 
665 ± 419 
(2-3 folds) 
683 ± 208 
(2-3 folds) 
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MGL - monoglyceride lipase 
NCIE - non-bullous congenital ichthyosiform 
erythroderma;  
NLSDI - Neutral Lipid Storage Disease with ichthyosis;  
NLSDM - Neutral Lipid Storage Disease with myopathy;  
NMD - nonsense-mediated mRNA decay;  
TAG - triacylglycerol 
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